<p>CRISPR, TALEN, and gene editing sound like the stuff of the future, but they are already changing medicine. What about zinc finger nucleases? That's what Sangamo Therapeutics uses to perform gene editing, and the tech recently earned the company a $3 billion deal. Today on Data Book, the origins of CRISPR and the Sangamo story.</p>

CRISPR, TALEN, and gene editing sound like the stuff of the future, but they are already changing medicine. What about zinc finger nucleases? That's what Sangamo Therapeutics uses to perform gene editing, and the tech recently earned the company a $3 billion deal. Today on Data Book, the origins of CRISPR and the Sangamo story.

S1 Ep3: The Gene-Editing Company That Didn't Need CRISPR

Data Book spotlights the best stories and insights in healthcare technology. Big data and artificial intelligence are changing medicine and the world, but innovation also brings grave cybersecurity concerns. Every other week, this Chief Healthcare Executive podcast explores the people and plots behind the health-tech evolution—and the solutions to its problems.

Share S1 Ep3: The Gene-Editing Company That Didn't Need CRISPR

Sign up to save your podcasts

S1 Ep3: The Gene-Editing Company That Didn't Need CRISPR

S1 Ep3: The Gene-Editing Company That Didn't Need CRISPR

More shows like Data Book

Planet Money